AVITA Medical (ASX:AVH) Reports Q4 and FY 2024 Financial Results
AVITA Medical (ASX:AVH) reports a 30% revenue increase in Q4 and FDA approvals, setting the stage for significant growth in FY 2025.
Category: Healthcare
Cochlear Limited (ASX:COH) Announces Half-Year 2024 Financial Results
Cochlear Limited (ASX:COH) reports a 5% revenue increase and an 8% interim dividend rise for the half year ended December 2024.
RECCE PHARMACEUTICALS Ltd (ASX:RCE) Pauses Trading Pending Further Announcement
RECCE PHARMACEUTICALS Ltd (ASX:RCE) has temporarily paused trading in its securities pending a further announcement.
Althea Group Holdings (ASX:AGH) Revises FY25 Financial Guidance
Althea Group Holdings (ASX:AGH) revises its FY25 revenue guidance to $26-$33 million and adjusts EBITDA expectations amidst strategic restructuring.
Neurotech International Ltd (ASX:NTI) Signs Development Agreement for Cannabinoid Therapies
Neurotech International Ltd (ASX:NTI) signs a development agreement with RH Pharma to develop cannabinoid therapies for pediatric neurological disorders.
Micro-X Limited (ASX:MX1) Announces $6.0M Capital Raising
Micro-X Limited (ASX:MX1) raises $6.0M through entitlement and placement offers to advance its medical imaging technology.
Pro Medicus Limited (ASX:PME) Reports 42.7% Profit Increase
Pro Medicus Limited (ASX:PME) reports a 42.7% increase in after-tax profit and announces a fully franked interim dividend.
Nuchev Limited (ASX:NUC) Appoints Nathan Cheong as CEO
Nuchev Limited (ASX:NUC) appoints Nathan Cheong as CEO, while Mick Myers transitions to COO and CFO roles.
Artrya Limited (ASX:AYA) Secures Multi-Year Contract with Sonic Healthcare Australia
Artrya Limited (ASX:AYA) secures a three-year agreement with Sonic Healthcare Australia to implement its Salix® platform for coronary artery disease assessment.
Echo IQ (ASX:EIQ) Receives $1.26M R&D Tax Incentive
Echo IQ (ASX:EIQ) secures $1.26 million R&D Tax Incentive for AI-driven cardiac technology development.